Pharmafile Logo
Pharmafocus logo
Advanced Search

NSCLC

Showing 15 posts of 129 posts found.

shutterstock_291014192

Asia-Pacific NSCLC market to more than double to $6.2bn by 2023

March 21, 2017
Manufacturing and Production, Research and Development, Sales and Marketing BMS, Eli Lilly, MSD, NSCLC, Yervoy, keytruda, opdivo

New research from intelligence provider GBI Research has indicated that the non-small cell lung cancer (NSCLC) market in the Asia-Pacific …

News
keytruda1

NICE knocks back MSD’s Keytruda for lung cancer indication

February 28, 2017
Research and Development, Sales and Marketing MSD, NICE, NSCLC, keytruda

MSD’s immunotherapy drug Keytruda (pembrolizumab) has been knocked back by the National Institute of Health and Care Excellence (NICE) for …

News
novartis_window

Novartis’ drug doubly effective as chemotherapy for treating lung cancer

December 8, 2016
NSCLC, Novartis, chemotherapy

Novartis have released that its drug, Zykadia, in Phase III trials, was twice as effective at slowing progression in advanced …

News
merck_and_co

MSD’s Keytruda given first FDA approval for first line treatment

October 25, 2016
Manufacturing and Production BMS, MSD, NSCLC, keytruda, opdivo

MSD, known as Merck in the US, has scored a big success in treating non-small cell lung cancer (NSCLC), with …

News

Merck KGaA and Pfizer team up with Debiopharm in lung cancer treatment

October 21, 2016
Medical Communications Debiopharm, Merck KGaA, NSCLC, Pfizer, lung cancer

Debiopharm International, the Swiss-based global biopharmaceutical group of five companies, announced that it would be entering into an agreement with …

News
shutterstock_159488225

Vaxon Biotech completes enrollment for mid-stage trial of lung cancer vaccine

March 16, 2016
Research and Development, Sales and Marketing NSCLC, immuno-oncology, vaxon biotech

Vaxon Biotech on Wednesday said it has completed the enrollments for mid-stage trials of its vaccine to treat non-small-cell lung …

News
xalkori

FDA approves Pfizer sNDA for Xalkori

March 14, 2016
Research and Development, Sales and Marketing Cancer, EMA, NSCLC, Pfizer, Xalkori (crizotinib)

The US FDA has approved Pfizer’s supplemental new drug application (sNDA) for its kinase inhibitor Xalkori in treating patients with …

News
AZ sign

AstraZeneca’s Tagrisso gets EU lung cancer sign-off

February 4, 2016
Sales and Marketing AstraZeneca, European Commission, NSCLC, Tagrisso, non-small cell lung cancer, osimertinib

The European Commission (EC) has granted conditional marketing authorisation to AstraZeneca’s Tagrisso to treat locally advanced or metastatic non-small cell …

News
Xalkori

Pfizer lung cancer treatment gets expanded EU approval

December 1, 2015
Research and Development, Sales and Marketing NSCLC, Pfizer, Xalkori, crizotinib, lung cancer, non-small cell lung cancer

Pfizer UK has received European Commission approval for a label update to expand use of Xalkori (crizotinib) to first-line treatment …

News
Chest x ray

Lilly cancer drug gets US approval

November 26, 2015
NSCLC, Portrazza, lilly, lung cancer, necitumumab, non-small cell lung cancer, oncology

Eli Lilly has received FDA approval for its monoclonal antibody Portrazza, in combination with gemcitabine and cisplatin, for patients with …

News

AstraZeneca halts lung cancer trials amidst safety concerns

October 13, 2015
Manufacturing and Production AZD9291, AstraZeneca, MEDI4736, NSCLC, drug safety, durvalumab, interstitial lung disease, lung cancer, non-small cell lung cancer

AstraZeneca is stopping two trials of a combination of two of its pipeline cancer treatments, after reports that the pairing …

News
lung cancer x ray

Lung cancer market to hit $10.9bn by 2021

September 10, 2015
Sales and Marketing AZD9291, GBI Research, GlobalData, NSCLC, industry analysis, industry intelligence, industry reports, keytruda, market intelligence lung cancer, market reports, market trends, non small cell lung cancer, non-small cell lung cancer, opdivo, world conference on lung cancer

The global market value for non-small cell lung cancer treatment will rise from $6.9 billion in 2014 to $10.9 billion …

News
AstraZeneca plaque

AstraZeneca lung cancer drug clears UK market access hurdle

September 4, 2015
Sales and Marketing AZD9291, AstraZeneca, Early Access to Medicines Scheme, MHRA, NSCLC, eams, lung cancer, non-small cell lung cancer

Follow @Pharmafocus

News
Opdivo

Bristol-Myers Squibb launches Opdivo in the UK for lung cancer

August 12, 2015
Sales and Marketing BMS, Bristol-Myers Squibb, NSCLC, immunotherapy, lung cancer, non small cell lung cancer, non-small cell lung cancer, opdivo

The immuno-oncology drug Opdivo is available in the UK for people with lung cancer, after Bristol-Myers Squibb launched the drug …

News
MedImmune building Cambridge

MedImmune and Mirati to partner on lung cancer combo

August 6, 2015
Research and Development AstraZeneca, Cancer, MedImmune, Mirati, Mirati Therapeutics, NSCLC, durvalumab, immuno-oncology, immunotherapy, lung cancer, mocetinostat

MedImmune is entering into an exclusive clinical trial collaboration with US-based Mirati Therapeutics to test a novel immuno-oncology combination in …

News

Latest content

FDA accepts new drug application for Orexo’s opioid overdose medication

November 28, 2023

Arcturus Therapeutics gains FDA ODD for cystic fibrosis treatment

November 28, 2023

Sanofi and Regeneron share results from phase 3 trial for Dupixent as COPD treatment

November 27, 2023

GSK shares results from phase 3 trial for Blenrep as multiple myeloma treatment

November 27, 2023

Alladapt Immunotherapeutics gains FDA Fast Track Designation for ADP101 as food allergy treatment

November 24, 2023